More on TSHA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.46 |
|
|||
| Open | $2.56 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $2.61 | ||||
| Day Low | $2.48 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 1,458,646 | ||||
- Form DEFA14A Taysha Gene Therapies,
- Form ARS Taysha Gene Therapies, For: Dec 31
- Form DEF 14A Taysha Gene Therapies, For: May 29
- Piper Sandler Starts Taysha Gene Therapies (TSHA) at Overweight, 'Innovative Gene Therapy Story'
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Taysha Gene Therapies (TSHA) PT Raised to $7 at Needham
- Form S-8 Taysha Gene Therapies,
- Form 8-K Taysha Gene Therapies, For: Mar 19
- Form 10-K Taysha Gene Therapies, For: Dec 31
- Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
Entities mentioned with TSHA
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- Needham & Company | View Related Stories »
- Jefferies & Co | View Related Stories »
- Goldman Sachs | View Related Stories »
- Chardan Capital Markets | View Related Stories »
- Show More...
